Authors
Troels K Bergmann, Henrik Gréen, Charlotte Brasch-Andersen, Mansoor R Mirza, Jørn Herrstedt, Berit Hølund, Andreas Du Bois, Per Damkier, Werner Vach, Kim Brosen, Curt Peterson
Publication date
2011/7
Journal
European journal of clinical pharmacology
Volume
67
Pages
693-700
Publisher
Springer-Verlag
Description
Purpose
Paclitaxel has a broad spectrum of anti-tumor activity and is useful in the treatment of ovarian, breast, and lung cancer. Paclitaxel is metabolized in the liver by CYP2C8 and CYP3A4 and transported by P-glycoprotein. The dose-limiting toxicities are neuropathy and neutropenia, but the interindividual variability in toxicity and also survival is large. The main purpose of this study was to investigate the impact of genetic variants in CYP2C8 and ABCB1 on toxicity and survival.
Methods
The 182 patients previously treated for ovarian cancer with carboplatin and paclitaxel in either the AGO-OVAR-9 or the NSGO-OC9804 trial in Denmark or Sweden were eligible for this study. Genotyping was carried out on formalin-fixed tissue. The patients’ toxicity profiles and survival data were derived from retrospective data. CYP2C8*3, ABCB1 C1236T, G2677T/A …
Total citations
Scholar articles
TK Bergmann, H Gréen, C Brasch-Andersen, MR Mirza… - European journal of clinical pharmacology, 2011